AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Myeloablative AgonistsBone Marrow TransplantationBone MarrowTransplantation, HomologousBone Marrow CellsGraft vs Host DiseaseTransplantation, AutologousTransplantation ConditioningWhole-Body IrradiationHematopoietic Stem Cell TransplantationBone and BonesBusulfanTransplantation ChimeraLeukemiaAnemia, AplasticTreatment OutcomeCombined Modality TherapyGraft SurvivalBone Marrow PurgingTissue DonorsHistocompatibility TestingLiver TransplantationCyclophosphamideHematologic NeoplasmsHistocompatibilityRecurrenceHematopoietic Stem CellsRetrospective StudiesBone Marrow DiseasesTransplantation, IsogeneicImmunosuppressive AgentsHematopoiesisRemission InductionTime FactorsSurvival AnalysisKidney TransplantationLeukemia, Myeloid, AcuteHepatic Veno-Occlusive DiseaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAcute DiseaseMice, Inbred C57BLAntineoplastic Combined Chemotherapy ProtocolsRadiation ChimeraPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Non-HodgkinStem Cell TransplantationSurvival RateBone Marrow ExaminationPrognosisFatal OutcomeCord Blood Stem Cell TransplantationLymphocyte DepletionGraft RejectionDisease-Free SurvivalFollow-Up StudiesLeukemia, MyeloidMyelodysplastic SyndromesBone RemodelingMelphalanBone Marrow NeoplasmsTransplantation ImmunologyGraft vs Host ReactionHLA AntigensImmunosuppressionLeukocyte TransfusionColony-Forming Units AssayHeart TransplantationT-LymphocytesHematologic DiseasesSevere Combined ImmunodeficiencyCyclosporineHodgkin DiseaseChimeraCarmustineEtoposideGranulocyte Colony-Stimulating FactorPeripheral Blood Stem Cell TransplantationGraft vs Tumor EffectMultiple MyelomaLung TransplantationLeukocyte CountCytarabineActuarial AnalysisBone DensityGraft vs Leukemia EffectProspective StudiesVincristineLymphocyte TransfusionAntigens, CD34MethotrexateLymphomaNuclear FamilyAntilymphocyte SerumCytomegalovirus InfectionsOrgan TransplantationRisk FactorsPancytopeniaCell DifferentiationInfectionHematopoietic Stem Cell Mobilization
Hematopoietic cell transplantationAutologous stem cell transHSCTChemotherapyGVHDLymph nodesTransplantsAcutePeripheral bloodLymphomaMalignantCyclophosphamideTumorTherapiesRenalDonorDosesSpleenMetastaticRadiationConclusionsMortalityChronicSymptomsDiagnosisOutcomesHigh-dosePlateletsLymphomasStem cellsSclerodermaClinicalPatientsRegimenComplicationsRelapseBloodViralTissuePrognosisDiseaseTherapyPatientCellCellsInfection
Hematopoietic cell transplantation6
Autologous stem cell trans2
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • In the prospective Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3 comparison of autologous HSCT with 12 successive monthly intravenous pulses of cyclophosphamide in 156 patients with early diffuse cutaneous systemic sclerosis, HCST was associated with higher treatment-related mortality than in the first year after treatment. (medscape.com)
HSCT6
Chemotherapy10
  • Bone marrow or stem cells that have been removed from a donor are carefully frozen and stored while the patient receives high-dose chemotherapy and sometimes whole-body radiation treatment. (lymphoma.ca)
  • Patients with lymphomas that are difficult to treat or resistant to standard therapy may benefit from chemotherapy or radiation therapy given in very high doses (myeloablative therapy). (lymphoma.ca)
  • High-dose chemotherapy, with or without myeloablative radiation therapy, is then administered to the patient to destroy the cancerous cells, as well as the healthy cells in the bone marrow. (lymphoma.ca)
  • Acute leukemia chemotherapy contains many potentially nephrotoxic molecules, especially when combined with other nephrotoxic treatments to which patients are regularly exposed. (plateforme-lea.fr)
  • Children with Down's syndrome have a higher risk of developing acute leukemia in the first years of life and are more prone to acute toxicities from chemotherapy treatments, despite reduced intensity protocols. (plateforme-lea.fr)
  • Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx ) is a type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) as part of a standardized chemotherapy regimen. (worldsbest.rehab)
  • Many of the side effects of chemotherapy can be traced to damage to normal cells that divide rapidly and are thus sensitive to anti-mitotic drugs: cells in the bone marrow, digestive tract and hair follicles. (worldsbest.rehab)
  • All chemotherapy regimens require that the recipient be capable of undergoing the treatment. (worldsbest.rehab)
  • Current chemotherapy regimens apply drug treatment in cycles, with the frequency and duration of treatments limited by toxicity. (worldsbest.rehab)
  • The stem cell transplants use the patient's own previously stored stem cells obtained from either the bone marrow or peripheral blood (PBSC) to replace the bone marrow, which is destroyed by the high-dose chemotherapy. (acco.org)
GVHD6
  • Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy) is associated with an increased risk of CMV infections. (bvsalud.org)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • What biomarkers for diagnosis and monitoring of treatment of GvHD? (cryostem.org)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
  • The overall response to ruxolitinib treatment for acute GVHD was 80%, 40% with partial response and 40% with complete remission. (scielo.org)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
Lymph nodes2
  • CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. (wikipedia.org)
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
Transplants3
Acute6
Peripheral blood2
Lymphoma8
  • Chronic lymphocytic leukemia may also develop a Richter's transformation i.e. conversion to a far more aggressive form that has the histopathology of diffuse large B cell lymphoma or Hodgkin's lymphoma. (wikipedia.org)
  • In contrast, an extramedullary tumor accompanied by marrow involvement below this threshold constitutes stage 4 lymphoma. (medscape.com)
  • Since the late 1960s, treatment outcomes for pediatric patients with non-Hodgkin lymphoma have steadily improved. (medscape.com)
  • In certain individuals with non-Hodgkin lymphoma, surgical resection and radiation therapy are also key components of definitive treatment. (medscape.com)
  • Most veterinary oncologists agree that unless palliation rather than extended remission is the goal of therapy, single agent treatment of lymphoma should be avoided. (vin.com)
  • Much of the information regarding efficacy of treatment for canine lymphoma has come from studies using combinations of cyclophosphamide, vincristine, and prednisone. (vin.com)
  • Лімфома Ходжкіна Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
Malignant2
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
Cyclophosphamide1
  • The medications fludarabine, cyclophosphamide, and rituximab were previously the initial treatment in those who are otherwise healthy. (wikipedia.org)
Tumor4
  • Here we report that while exogenous administration of LPS was able to enhance adoptively transferred CD8 + T cells' tumor destruction, LPS treatment alone did not replace individual components of the tripartite ACT regimen, or obviate TBI. (biomedcentral.com)
  • Because only a fraction of the cells in a tumor die with each treatment (fractional kill), repeated doses must be administered to continue to reduce the size of the tumor. (worldsbest.rehab)
  • Patients also receive local radiation to tumor sites, followed by posttransplant maintenance treatment with 13-cis-retinoic acid (Accutane). (acco.org)
  • In stage 4 disease, the neuroblastoma tumor cells have already spread (or metastasized) to other sites in the body, such as the bone or bone marrow. (acco.org)
Therapies4
  • Aggressive "biological therapies" are immunogenic, but their effects fade over time [ 6 ]. (biomedcentral.com)
  • Director of Bone Marrow Transplant and Cell Therapies, Royal Manchester Children's Hospital, United Kingdom. (ebmt.org)
  • Improved knowledge about these genetic susceptibilities may help define more personalized therapies that balance the effectiveness of treatment with the risk of late complications. (plateforme-lea.fr)
  • Because there are no established effective treatments for such patients, therapies listed above and/or highly experimental therapies with unknown risks may be appropriate for such patients. (acco.org)
Renal2
Donor3
  • This means that they receive stem cells (either their own stem cells that were stored prior to myeloablative therapy or stem cells from a donor) to replenish their bone marrow which had previously been destroyed by the high-dose therapy. (lymphoma.ca)
  • Stem cells or bone marrow derived from a donor (allogeneic transplant) are usually collected immediately before use and not stored for any length of time. (lymphoma.ca)
  • The harvested stem cells or bone marrow (obtained from either the patient's own healthy cells or from a donor) are then transplanted intravenously into the bloodstream of the patient. (lymphoma.ca)
Doses1
  • The first-line treatment is high doses of corticosteroids. (scielo.org)
Spleen1
Metastatic3
  • Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. (stanfordchildrens.org)
  • There are limited studies examining the outcomes specific to patients with RMS metastatic to bone marrow despite an incidence of 6% at diagnosis. (stanfordchildrens.org)
  • Age 10years, alveolar histology, FOXO1 fusion presence, unfavorable primary location, higher Oberlin score, and lack of radiation were identified as poor prognostic/predictive characteristics.This study represents the largest analysis of RMS metastatic to bone marrow, defining the poor prognostic outcome for these patients. (stanfordchildrens.org)
Radiation2
  • 83% (n=149) received radiation as a treatment modality. (stanfordchildrens.org)
  • Systemic therapy is often used in conjunction with other modalities that constitute local therapy (i.e., treatments whose efficacy is confined to the anatomic area where they are applied) for cancer such as radiation therapy, surgery or hyperthermia therapy. (worldsbest.rehab)
Conclusions1
  • Many studies on scleroderma show some promise, but small sample sizes make it difficult to draw strong conclusions about treatment benefits. (mountsinai.org)
Mortality3
  • The rationale for the proposed research is that when we are able to identify patients who are at particularly high risk for unresponsiveness to standard treatment and subsequent mortality, we can porpose customized treatment plans. (cryostem.org)
  • Added to this, there are patients who do not improve on any immunosuppressive treatment, with subsequent deteriorated quality of life and high mortality. (scielo.org)
  • Demographic, previous treatment, response and mortality data were collected. (scielo.org)
Chronic2
Symptoms3
  • Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams. (mims.com)
  • Doctors have made progress developing treatments to reduce symptoms and prolong life, but there is no cure. (mountsinai.org)
  • Treatment involves a combination approach to treat the immune response, improve circulation, and stop the progression of skin symptoms. (mountsinai.org)
Diagnosis3
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • Once a definitive diagnosis has been obtained and after the patient has been staged accurately, the veterinarian should schedule a discussion with the owner regarding prognosis and treatment. (vin.com)
  • Disease is likely to be disseminated at the time of presentation, and diagnosis is usually based on lymph node or bone marrow biopsy or both. (msdmanuals.com)
Outcomes1
  • Aim: To Describe our population of patients with AML and report the outcomes of our treatments. (scielo.org)
High-dose1
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
Platelets2
  • Less commonly, the disease comes to light only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. (wikipedia.org)
  • At times, very advanced and nonresponsive lymphomas may be treated using a bone marrow transplant (marrow is the soft tissue in the centre of large bones that produces white and red blood cells and platelets) or stem-cell transplantation (the cells that develop blood). (lymphoma.ca)
Lymphomas1
Stem cells5
Scleroderma2
  • The drug was approved in Europe in 2007 for the treatment of skin ulcers related to scleroderma. (mountsinai.org)
  • Linear scleroderma may also involve muscle or bone. (mountsinai.org)
Clinical5
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
  • The clinical behavior of neuroblastoma is highly variable, with some tumors being easily treatable, but the majority being very aggressive. (acco.org)
  • Most pediatric oncologists agree that even with optimal current intensive therapy, the aggressive nature of this disease warrants entering as many of these children as possible on clinical trials that may identify improved forms of treatment. (acco.org)
  • Phase III clinical trials focus on a particular disease and ask specific scientific questions, with the long-term goal of defining the best approach to treatment by comparing one therapy to another. (acco.org)
  • Participation in clinical trials allows patients access to state-of-the-art treatment for that disease and also the chance of being among the first to benefit from a new treatment that may be more effective. (acco.org)
Patients11
  • Complications include a low level of antibodies in the bloodstream (hypogammaglobulinemia), leading to recurrent infection, warm autoimmune hemolytic anemia in 10-15% of patients, and bone marrow failure. (wikipedia.org)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Successful allogeneic transplantation of patients with suspected prior invasive mold infection. (uchicago.edu)
  • CD patients maintained high remission rates for 3-24 months after transplantation. (biomedcentral.com)
  • The precise identification of patients with each of these late effects in the LEA cohort, as well as their detailed description in terms of variables associated with the patient, disease and treatment will greatly facilitate the study at the genome level. (plateforme-lea.fr)
  • From the patients of the LEA cohort, the results of patients with trisomy 21 will be compared to patients without trisomy 21 matched on age, characteristics of leukemia and treatments received. (plateforme-lea.fr)
  • Dr. Dora Ho specializes in infection complications in immunocompromised patients, such as those with bone marrow transplant, solid organ transplant, cancers and other forms of immunodeficiency. (stanford.edu)
  • We will validate this predictive panel on 300 matched cGvHD patients samples pre-treatment and 3 months post-treatment. (cryostem.org)
  • Ruxolitinib treatment in patients with a very poor prognosis showed encouraging results. (scielo.org)
  • Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. (scielo.org)
  • These patients may be eligible for therapy deintensification or early pursuit of novel treatments/approaches that are desperately needed. (stanfordchildrens.org)
Regimen1
  • A non-myeloablative lymphodepleting preparative regimen with 5Gy TBI prior to an ACT regimen can induce destruction of B16F10 melanoma in mice by removing cytokine sinks, depleting suppressive T reg cells, transiently ablating myeloid derived suppressor cells (MDSCs) and activating the innate immune system [ 11 ]. (biomedcentral.com)
Complications3
  • There is no established treatment for these individuals except monitoring for development of the disorder's various complications (see treatment of MBL complications) and for their progression to CLL. (wikipedia.org)
  • Links have now been established between the treatments used and the specific complications, but significant inter-individual variability is observed for the same treatment. (plateforme-lea.fr)
  • Current treatment of systemic sclerosis is directed toward managing complications and providing symptomatic relief. (medscape.com)
Relapse2
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • Conforming with an aggressive disease, there was a frank disease relapse immediately after the transplant, which failed to respond to bridging treatment including venetoclax. (ebmt.org)
Blood3
  • A copy of the protocol to be administered, with scheduled treatments, rechecks, and blood counts, will assist owners in remembering much of this information. (vin.com)
  • He had a busulphan based myeloablative cord blood stem cell transplant with a 6/8 mismatched cord blood. (ebmt.org)
  • In such an intractable, chemo refractory, early post-transplant relapsed disease, where palliative treatment was seemingly the only available option, he was offered an experimental approach with GRANS under which, he was given a T replete, 6/8 mismatched unrelated cord blood stem cell transplant with the administration of third-party pooled granulocytes around the D0. (ebmt.org)
Viral1
  • C) Viral reactivation and send extended screen for viral PCRs to guide antiviral treatment. (ebmt.org)
Tissue4
  • Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • [18] Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Disease-modifying treatment aims at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis. (medscape.com)
Prognosis1
Disease8
  • Early-stage CLL in asymptomatic cases responds better to careful observation, as there is no evidence that early intervention treatment can alter the course of the disease. (wikipedia.org)
  • In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
  • Osteoporosis Osteoporosis is a progressive metabolic bone disease that decreases bone mineral density (bone mass per unit volume), with deterioration of bone structure. (merckmanuals.com)
  • Prognostic factors include stage and substage of disease, histologic type, immunophenotype (B-cell versus T-cell), presence of hypercalcemia, response to therapy, pre-treatment steroid therapy, and possibly gender. (vin.com)
  • The cause and course of the disease is unclear, and more research is needed to assess treatment options. (mountsinai.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system , e.g., the bone marrow and the thymus ) itself, and the lungs in the form of immune-mediated pneumonitis . (wikipedia.org)
  • In addition, a range of disease-modifying treatments have been investigated. (medscape.com)
  • The treatment of low or intermediate risk tumors is very different from treating high-risk disease. (acco.org)
Therapy2
Patient4
  • SCs have been found to inhibit intestinal inflammation, promote long-term intestinal mucosal healing, and significantly improve patient quality of life, making them a valuable alternative CD treatment. (biomedcentral.com)
  • To combat this problem, the patient receives a bone marrow or a stem-cell transplant. (lymphoma.ca)
  • ST2, Reg3α, TNFR1, IL-6 will be validated on 300 matched aGvHD patient samples pre-treatment and 1month post-treatment. (cryostem.org)
  • These large studies test a new treatment/ procedure in comparison to the current standard treatment by using randomized assignment to determine which of these approaches offer an improvement in terms of outcome and patient safety as compared to the current standard. (acco.org)
Cell3
  • Marrow or cell transplantation is done to replace healthy cells that have been destroyed by cancer treatment. (lymphoma.ca)
  • What is the Difference Between a Bone Marrow Transplant and a Stem-cell Transplant? (lymphoma.ca)
  • Collectively, our results identify how and when to administer TLR agonists to augment T cell-based immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. (biomedcentral.com)
Cells2
  • With types of NHL that have spread to the bloodstream or bone marrow, it may be difficult to obtain uncontaminated cells or cells that can be used, even after treating them in a laboratory to remove or kill the NHL cells. (lymphoma.ca)
  • This process kills all or most normal stem and bone marrow, while destroying cancer cells. (lymphoma.ca)
Infection1
  • During the recovery period, all of the body's systems must be carefully monitored for rejection, infection and the need for any supportive treatments. (lymphoma.ca)